Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 17/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6222747 | 1.00 | CA2 (0.59) | CA2CA1CA5ACA7CA9 | |
| SCHEMBL6277563 | 1.00 | CA2 (0.59) | CA2CA1CA5ACA7CA9 | |
| SCHEMBL6288709 | 0.92 | CA2 (0.52) | CA2CA1CA5ACA7CA9 | |
| SCHEMBL18974594 | 0.86 | CA2 (0.55) | CA2CA1CA5ACA7CA9 | |
| SCHEMBL668970 | 0.85 | — | — | |
| SCHEMBL23462257 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL29678816 | 0.82 | — | — | |
| SCHEMBL6285121 | 0.81 | CA2 (0.39) | CA2CA1CA5ACA7CA9 | |
| SCHEMBL6277726 | 0.81 | CA2 (0.39) | CA2CA1CA5ACA7CA9 | |
| Methanesulfonamide SCHEMBL10759634 | 0.80 | CA1 (0.42) | CA2CA1CA5ACA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119954829-A | MTORC1 modulators and uses thereof | 艾奥维安制药公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-115776907-B | MTORC1 modulators and uses thereof | 艾奥维安制药公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-3426246-B1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RES INST (TW) | 2024-05-01 | — | — | EP | disclosed |
| US-20240002399-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2024-01-04 | — | — | US | disclosed |
| US-11634432-B2 | mTORC1 modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (CA) | 2023-04-25 | — | — | US | disclosed |
| US-11603377-B2 | MTORC1 modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-03-14 | — | — | US | disclosed |
| EP-4126229-A1 | MTORC1 MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20220332727-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2022-10-20 | — | — | US | disclosed |
| US-20220235069-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2022-07-28 | — | — | US | disclosed |
| WO-2021195599-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2017155910-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2017-09-14 | — | — | WO | disclosed |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2017-09-07 | — | — | US | disclosed |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2017-09-07 | — | — | US | disclosed |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2017-09-07 | — | — | US | disclosed |
| US-6887903-B1 | N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them | DOMPE S.P.A. (IT) | 2005-05-03 | — | — | US | disclosed |
| US-6881755-B2 | N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them | Dompé S.p.A. (IT) | 2005-04-19 | — | — | US | disclosed |
| US-20030216392-A1 | N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them | DOMPE S.P.A. | 2003-11-20 | — | — | US | disclosed |
| EP-1123276-B1 | N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | DOMPE SPA (IT) | 2003-01-08 | — | — | EP | disclosed |
| EP-1123276-A1 | N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | Dompe' S.P.A. (IT) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000024710-A1 | N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | DOMPE' S.P.A. (IT) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235069-A1 | MTORC1 MODULATORS AND USES THEREOF | MTOR, RPTOR, RICTOR | CA2 4043/4885CA1 4771/4885CA5A 3634/4885 |
| US-20220332727-A1 | MTORC1 MODULATORS AND USES THEREOF | MTOR, RPTOR, RICTOR | CA2 4043/4885CA1 4771/4885CA5A 3634/4885 |
| US-20030216392-A1 | N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them | ELANE, MPO, FPR1 | CA2 2887/4885CA1 3899/4885CA5A 3265/4885 |
| US-11603377-B2 | MTORC1 modulators and uses thereof | MTOR, RPTOR, RICTOR | CA2 3297/4885CA1 4786/4885CA5A 3547/4885 |
| US-11634432-B2 | mTORC1 modulators and uses thereof | MTOR, RPTOR, RICTOR | CA2 3288/4885CA1 4730/4885CA5A 3426/4885 |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | OPRL1, OPRD1, OPRK1 | CA2 4192/4885CA1 4311/4885CA5A 1467/4885 |
| US-20240002399-A1 | MTORC1 MODULATORS AND USES THEREOF | MTOR, RPTOR, RICTOR | CA2 3288/4885CA1 4730/4885CA5A 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.